Answers are grounded in this paper and cite their sources.
Explores modifications to improve plasma stability and potency in cancer immunotherapy agents.
The potent butyrophilin ligand, (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP), is a potential cancer immunotherapy agent, but it lacks plasma stability and membrane permeability. Aryl phosphonamidate prodrugs of a key HMBPP analog have improved plasma stability but poor cellular uptake, while aryl phosphonester prodrugs have improved uptake but lack plasma stability. Here, tuning the benzoic acid substructure of a phosphonester prodrug was explored. Twenty-one aryl phosphonester derivatives were prepared in allylic alcohol (8a-k) and allylic acetate (9a-k) forms. Testing revealed that this strategy can provide compounds with high potency for expansion of γ9δ2 T cells (8d, EC₅₀ = 0.86 nM) and interferon γ production in response to loaded K562 cells (8d, EC₅₀ = 2.3 nM). Importantly, these compounds display improved plasma stability (130-fold range; 8d, t1/2 > 24 h), showing the importance of the benzoic acid position for plasma versus cellular metabolism. These findings enable next-generation prodrugs with improved stability and potency.
No takes yet. Share an insight, caveat, or question.
Kintigh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: